_1782605483653-86ykd14Q.png)
No drug class in recent memory has put benefits managers in a harder spot than the GLP-1s. Ozempic, Wegovy, Mounjaro — originally approved for type 2 diabetes, now famous for something else entirely — have become the most consequential line item in Canadian drug plans almost overnight. The decision facing employers is genuinely difficult, and it deserves more than a reflexive yes or a reflexive no.
Start with the scale of the thing. Benefits analysts attribute roughly 1.5 to 3 percentage points of total plan trend to specialty and weight-management drugs, and GLP-1s are the loudest voice in that chorus. A member on one of these medications can cost a plan in the range of $3,000 to $5,000 a year — and unlike a course of antibiotics, it's often an ongoing, possibly indefinite, expense. Multiply that by even a small fraction of a workforce and the math gets serious fast.
Two questions hiding inside one decision
The reason this feels so thorny is that employers tend to collapse two separate questions into one.
The first is a clinical and equity question: obesity is now widely recognized by medical bodies as a chronic disease, and GLP-1s are, by the evidence, remarkably effective at treating it — with emerging data on cardiovascular and other benefits. Declining to cover an effective treatment for a recognized disease sits uncomfortably, especially for the same plan that readily covers medications for the conditions obesity contributes to.
The second is a financial and sustainability question: a benefit that grows without guardrails can become unaffordable, and an unaffordable benefit eventually gets cut for everyone. Generosity that bankrupts the plan helps no one.
The mistake is answering only one of these. A good GLP-1 strategy answers both — covering the treatment and controlling the spend.
The realistic menu of options
Employers aren't actually choosing between "cover everything" and "cover nothing." The real menu is more textured, and the middle is where most defensible decisions land:
- Full coverage, unmanaged. Simplest, most generous, and the fastest route to an ugly renewal. Rarely advisable without guardrails.
- Prior authorization. Coverage gated by clinical criteria — a documented diagnosis, BMI thresholds, sometimes evidence of prior interventions. This is the single most important lever. It ensures the drug goes to members for whom it's clinically indicated rather than funding every off-label request.
- Step therapy and quantity limits. Requiring appropriate dosing escalation and capping quantities to prevent waste and stockpiling.
- Annual or lifetime maximums on weight-management indications. A dollar ceiling that preserves access while capping the plan's exposure.
- Coverage for diabetes indications, managed coverage for obesity. Some plans distinguish by indication — a defensible, if administratively careful, path.
- Carve-out. Excluding weight-management use entirely. Cleanest on cost, hardest to defend on equity, and increasingly conspicuous as peers cover it.
The instinct of an experienced advisor is rarely the extremes. It's prior authorization plus sensible limits — the combination that keeps the benefit available to the people who clinically need it while protecting the plan from the people who don't.
The ROI argument is real but unsettled
Proponents make a genuine case: treating obesity may reduce downstream costs — diabetes, cardiovascular events, joint replacements, disability claims. There's credible research pointing this direction, and for some populations the long-run economics could plausibly work.
But honesty requires acknowledging what we don't yet know. The long-term adherence picture is messy — a substantial share of patients discontinue within a year or two, and weight often returns when they do. The "you save later" argument depends on sustained use that the real-world data doesn't yet guarantee, and on the member staying with your plan long enough for the employer to capture the downstream savings — which, in a mobile workforce, they frequently don't. The ROI case is plausible. It is not yet proven at the level of confidence that justifies an unmanaged blank cheque.
What insurers are quietly doing
It's worth knowing how the other side of the table is moving, because it shapes your options. Carriers have been steadily tightening: more prior-authorization requirements, more managed formularies, more scrutiny of weight-management indications specifically. Some have introduced GLP-1-specific programs. The practical implication is that "do nothing" isn't actually static — your insurer may be adjusting the terms around you, and you're better off shaping that deliberately than discovering it at renewal.
The conversation you have to get right
Whatever you decide, the communication matters as much as the policy. GLP-1s are emotionally and personally charged in a way that, say, cholesterol medication is not. A poorly explained restriction reads as a judgment about people's bodies; a well-explained one reads as responsible stewardship of a shared resource.
The framing that works is honest and specific: here is what the plan covers, here are the clinical criteria, here is why we've built it this way, and here is how to apply if it's right for you. Employees don't need the plan to cover everything. They need to understand the rules and trust that the rules are fair.
A decision, not a default
The worst outcome is the one that happens by accident — a plan that covers GLP-1s with no controls because no one made an active choice, followed two renewals later by a panicked cut that lands hardest on the members already relying on the drug. That whipsaw is avoidable.
The better path is a deliberate one: decide what to cover and under what criteria, build the prior-authorization and limit structure to match, communicate it clearly, and revisit it as the evidence matures — because it is maturing quickly. This is a genuinely hard call. It deserves to be made on purpose.
